加载中
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
前收盘价
US$4.70
+US$0.15 · +3.30%
盘中时间采用ET。市场数据可能有所延迟。
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
日内区间
当前US$4.70
52周区间
当前US$4.70
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
51
合理估值
情绪
42
多空交织
风险
71
高风险
动量
27
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
日内区间
当前US$4.70
52周区间
当前US$4.70
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 285.4万 USD | 237万 USD | 238万 USD | 121.2万 USD |
| 毛利 | 285.4万 USD | 237万 USD | 238万 USD | 121.2万 USD |
| 研究与开发 | 1.37亿 USD | 6296.6万 USD | 3179.9万 USD | 1865.7万 USD |
| 销售、一般及管理费用 | 2640.9万 USD | 1716.8万 USD | 1069.5万 USD | 646.4万 USD |
| 营业费用 | 1.63亿 USD | 8013.4万 USD | 4249.4万 USD | 2512.1万 USD |
| 利息收入 | 1693.3万 USD | 1212.3万 USD | 416.5万 USD | 20.5万 USD |
| 折旧和摊销 | 18.8万 USD | 8.9万 USD | 6万 USD | 7000 USD |
| 营业利润 | −1.6亿 USD | −7776.4万 USD | −4011.4万 USD | −2390.9万 USD |
| 净利润 | −1.43亿 USD | −6280.6万 USD | −2053.7万 USD | −2386.8万 USD |
公司数据更新于 2026年10月12日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI955.28万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM428.28万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF265.22万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO133.91万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB127.88万0.01%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA95.36万0.00%218.24亿 USD0.03%US$32.79+0.40%
Fidelity Fundamental Small-Mid Cap ETFFFSM76.96万0.05%14.4亿 USD0.43%US$34.13+0.62%
Dimensional - US Small Cap ETFDFAS68.48万0.00%338.69亿 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
